Generic Medicine Info
Should be taken with food.
Severe hepatic impairment. Concurrent administration with St. John's Wort.
Special Precautions
Patients with history of serious behavioural problems. Patients who are not receiving enzyme-inducing drugs. Avoid abrupt withdrawal (may taper off treatment over a period of 2-3 weeks), rapid titration or large dose increments. Mild to moderate hepatic impairment. Children and elderly. Pregnancy and lactation. Patient Counselling This drug may cause dizziness or drowsiness, if affected, do not drive or operate machinery. Monitoring Parameters Monitor for signs and symptoms of emergence or worsening of depression, suicidal ideation and behaviour, or unusual changes in mood or behaviour; therapeutic efficacy (seizure activity, type, duration); LFTs (periodically). May consider obtaining tiagabine plasma levels before and after changes in the therapeutic regimen.
Adverse Reactions
Significant: Suicidal ideation and behaviour, spontaneous bruising, moderately severe to incapacitating generalised weakness, CNS depression (impaired physical or mental abilities). Rarely, visual field defects. Eye disorders: Blurred vision. Gastrointestinal disorders: Nausea, diarrhoea, vomiting, abdominal pain. General disorders and administration site conditions: Tiredness. Injury, poisoning and procedural complications: Accidental injury. Musculoskeletal and connective tissue disorders: Muscle twitching. Nervous system disorders: Dizziness, tremor, ataxia, abnormal gait, speech disorder. Psychiatric disorders: Nervousness, concentration difficulties, depressed mood, emotional lability, confusion, insomnia, hostility or aggression. Respiratory, thoracic and mediastinal disorders: Pharyngitis.
Potentially Fatal: Rarely, severe skin reactions (e.g. Stevens-Johnson syndrome).
Drug Interactions
Decreased plasma concentration with hepatic enzyme-inducing anti-epileptics (e.g. phenytoin, carbamazepine, phenobarbital, primidone).
CIMS Class
ATC Classification
N03AG06 - tiagabine ; Belongs to the class of fatty acid derivatives antiepileptic.
Disclaimer: This information is independently developed by CIMS based on tiagabine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in